Epidemiological data and utilization patterns of anti-TNF alpha therapy in the Hungarian ulcerative colitis population between 2012-2016

Péter Kunovszki, Kata Judit Szántó, Judit Gimesi-Országh, Péter Takács, András Borsi, Anita Bálint, Klaudia Farkas, Ágnes Milassin, Péter L. Lakatos, Tamás Szamosi, Tamás Molnár

Research output: Contribution to journalArticle

Abstract

Background: Anti-TNF therapy is efficacious in the maintenance of remission in ulcerative colitis (UC); however, long-term data on real-life use of these agents are lacking. Methods: This observational, retrospective, epidemiological study using the National Health Insurance Fund social security database aimed to understand patient characteristics and therapeutic patterns of anti-TNF therapy. Data of adult Hungarian, UC patients treated with anti-TNF agents (IFX-infliximab, ADA-adalimumab) between 2012 and 2016 were analyzed. Results: Five hundred and sixty-eight UC patients were identified. Approximately 70-80% of the patients reached maintenance therapy. A large proportion of patients stopped therapy after 10 to 12 months due to the reimbursement policy. Corticosteroid use decreased significantly after the initiation of biological therapy. The dose-escalation rate was 19.8% for ADA and 10.9% for IFX, respectively, and was performed earlier along the treatment timeline for patients on ADA. In the present study, the rate of primary non-response (PNR) was 11.6% and the rate of secondary loss of response (LOR) was 36.5%. Summary: Treatment length is in correspondence with the Hungarian reimbursement policies. The mandatory stop of treatment in the reimbursement policy is suboptimal in UC patients requiring biological therapy. The corticosteroid-sparing effect of biological therapy was demonstrated.

Original languageEnglish
Pages (from-to)443-449
Number of pages7
JournalExpert Opinion on Biological Therapy
Volume20
Issue number4
DOIs
Publication statusPublished - Apr 2 2020

    Fingerprint

Keywords

  • Anti-TNF therapy
  • corticosteroids
  • loss of response
  • primary non response
  • ulcerative colitis

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this